QED Investigative Site Trials

QED Investigative Site	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

BORBATH, Ivan

SAUNA, NCT05701241: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Recruiting

270

Europe

Somatostatin analog, lanreotide, octreotide, sandostatin, somatuline

University Hospital, Antwerp, Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre

Gastroenteropancreatic Neuroendocrine Tumor

04/29

04/34

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed

571

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

10/24

ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting

288

Europe, Canada, US, RoW

RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide

RayzeBio, Inc., RayzeBio, Inc.

GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET

12/25

07/28

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament

Biliary Tract Neoplasms

06/27

06/28

SEVILLA, NCT06529718: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not yet recruiting

Europe

Ivonescimab, FOLFOX regimen

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics

Biliary Tract Cancer

08/27

01/29

NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting

134

Europe

Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin

Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Metastatic Pancreatic Ductal Adenocarcinoma

12/26

12/27

STEREOPAC, NCT05083247: Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Recruiting

256

Europe

mFOLFIRINOX or Gemcitabine nab-paclitaxel, mFFX or Gem/Nab-p, Isotoxic High-Dose (iHD)-SBRT, Surgery

Erasme University Hospital, Jules Bordet Institute, Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma

12/27

12/30

OPTIMIZE-1, NCT04888312 / 2020-005182-14: Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients

Active, not recruiting

1/2

Europe

CD40 agonist mitazalimab in combination with chemotherapy, ADC-1013, JNJ-64457107

Alligator Bioscience AB, Theradex, BC Platforms

Metastatic Pancreatic Ductal Adenocarcinoma

01/24

06/26

NCT04241835: A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Recruiting

Europe, US

Tazemetostat, EPZ-6438, IPN60200, Tazverik®

Epizyme, Inc., Sponsor GmbH

Hepatic Impairment, Advanced Malignant Solid Tumor

05/25

06/25

NCT05276037: Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

Recruiting

N/A

350

Europe

Liver transplantation

University of Liege, University Hospital, Ghent, Free University of Brussels, University Hospital, Antwerp, Universitaire Ziekenhuizen Leuven, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Hepatocellular Carcinoma

01/25

01/29

Le, Tuan N

HPV9vxFSW, NCT06681636: Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure

Not yet recruiting

300

RoW

Human papillomavirus 9-valent vaccine, Recombinant, Gardasil 9

National Institute of Hygiene and Epidemiology, Vietnam, Murdoch Childrens Research Institute, CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES, Hai phong Center for Disease Control

HPV Infection, Cervical Cancer, Anogenital Cancer, Anogenital Warts

10/26

12/27

NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting

134

Europe

Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin

Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Metastatic Pancreatic Ductal Adenocarcinoma

12/26

12/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

BORBATH, Ivan

SAUNA, NCT05701241: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Recruiting

270

Europe

Somatostatin analog, lanreotide, octreotide, sandostatin, somatuline

University Hospital, Antwerp, Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre

Gastroenteropancreatic Neuroendocrine Tumor

04/29

04/34

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed

571

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

10/24

ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting

288

Europe, Canada, US, RoW

RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide

RayzeBio, Inc., RayzeBio, Inc.

GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET

12/25

07/28

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

Biliary Tract Neoplasms

06/27

06/28

SEVILLA, NCT06529718: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not yet recruiting

Europe

Ivonescimab, FOLFOX regimen

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics

Biliary Tract Cancer

08/27

01/29

NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting

134

Europe

Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin

Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Metastatic Pancreatic Ductal Adenocarcinoma

12/26

12/27

STEREOPAC, NCT05083247: Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Recruiting

256

Europe

mFOLFIRINOX or Gemcitabine nab-paclitaxel, mFFX or Gem/Nab-p, Isotoxic High-Dose (iHD)-SBRT, Surgery

Erasme University Hospital, Jules Bordet Institute, Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma

12/27

12/30

OPTIMIZE-1, NCT04888312 / 2020-005182-14: Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients

Active, not recruiting

1/2

Europe

CD40 agonist mitazalimab in combination with chemotherapy, ADC-1013, JNJ-64457107

Alligator Bioscience AB, Theradex, BC Platforms

Metastatic Pancreatic Ductal Adenocarcinoma

01/24

06/26

Recruiting

Europe, US

Tazemetostat, EPZ-6438, IPN60200, Tazverik®

Epizyme, Inc., Sponsor GmbH

Hepatic Impairment, Advanced Malignant Solid Tumor

05/25

06/25

NCT05276037: Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

Recruiting

N/A

350

Europe

Liver transplantation

Hepatocellular Carcinoma

01/25

01/29

Le, Tuan N

HPV9vxFSW, NCT06681636: Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure

Not yet recruiting

300

RoW

Human papillomavirus 9-valent vaccine, Recombinant, Gardasil 9

National Institute of Hygiene and Epidemiology, Vietnam, Murdoch Childrens Research Institute, CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES, Hai phong Center for Disease Control

HPV Infection, Cervical Cancer, Anogenital Cancer, Anogenital Warts

10/26

12/27

NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting

134

Europe

Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin

Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels

Metastatic Pancreatic Ductal Adenocarcinoma

12/26

12/27



	Diseases Companies Products Productz Mechanisms of Action Sites